Welcome to our dedicated page for Zentek Ltd. news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek Ltd. stock.
Zentek Ltd. (Nasdaq: ZTEK, TSX-V: ZEN) is an intellectual property development and commercialization company focusing on next-generation healthcare solutions for prevention, detection, and treatment. Zentek is at the forefront of commercializing ZENGuard, a groundbreaking coating with 99% antimicrobial effectiveness, including activity against COVID-19. This technology has applications in a variety of fields, including surgical masks and HVAC systems.
The company operates a state-of-the-art production facility in Guelph, Ontario, and is ISO 13485:2016 certified. Zentek has developed a synergistic relationship with McMaster University to leverage an exclusive global license for their aptamer-based rapid pathogen detection technology. This partnership has led to promising results, including the C19HBA aptamer, which has shown therapeutic potential against SARS-CoV-2, outperforming leading monoclonal antibodies in preclinical trials.
Through its wholly-owned subsidiary Triera Biosciences Ltd., Zentek continues to advance its aptamer technology. Notably, their C19HBA aptamer has demonstrated robust preclinical efficacy in both prophylactic and therapeutic settings against various SARS-CoV-2 variants, including Omicron XBB 1.5. The company is now moving towards Phase 1 clinical trials and exploring further applications for their platform in infectious diseases and oncology.
In addition to healthcare, Zentek has made significant strides in the HVAC industry. The company's ZenGUARD™ Enhanced Air Filters aim to improve air quality without increasing energy consumption or emissions. Zentek's commitment to innovation is further evidenced by a series of partnerships and distribution agreements, including collaborations with Medwell Solutions LLC and DCL Supply Ltd. These partnerships aim to expand the market reach of Zentek's antimicrobial technologies.
Recent Achievements:
- Significant progress in preclinical trials for C19HBA aptamer as a therapeutic for SARS-CoV-2.
- A promising safety and toxicity profile for the C19HBA aptamer in preclinical tests.
- Exclusive distribution agreements for ZenGUARD™ Enhanced Surgical Masks in the U.S. with Medwell Solutions LLC and DCL Supply Ltd.
- Launch preparations for ZenGUARD™ Enhanced Air Filters in the HVAC market.
- Second patent for their GO-Ag+ nanocomposite as an antimicrobial agent, expanding its potential applications to both human and veterinary medicine.
Zentek continues to focus on commercializing its proprietary technologies, aiming to provide significant health benefits while also addressing environmental concerns. By offering innovative, safer, and greener products, Zentek seeks to give its commercial partners a competitive edge in their respective markets.
Zentek Ltd. (NASDAQ: ZTEK) announced the grand opening of its industrial-scale ZenGUARD antimicrobial production facility in Guelph, Ontario, scheduled for June 17, 2022. This facility is among the largest in the world for nanomaterials-based manufacturing and supports Zentek's trajectory from laboratory to commercial success. ZenGUARD is a patent-pending coating with 99% antimicrobial effectiveness, targeting the growing demand for transmission prevention products. The company is also exploring applications in the HVAC market to generate additional revenue.
Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN) announced that McMaster University received two NSERC Grants for its aptamer-based rapid detection technology. The Alliance Missions Grant totals $1,000,000, while the Idea to Innovation Grant amounts to $350,000, with Zentek contributing $140,000. These funds will further enhance the commercialization of the rapid diagnostic platform, particularly in optimizing chip synthesis and developing a universal aptamer for COVID variants. This endorsement underlines the potential of Zentek's technology in the healthcare sector.
Zentek Ltd. (Nasdaq:ZTEK) announces the appointment of Wendy Ford as the new Chief Financial Officer, effective immediately. With over 30 years of experience, she aims to optimize operations and enhance shareholder value. Brian Bosse transitions to Chief Operations Officer, further strengthening leadership during a pivotal growth phase following Zentek's recent Nasdaq listing. Additionally, Moe Deib will join as Director of Global Healthcare Sales on May 24, 2022, focusing on selling ZenGUARD™ technology. ZenGUARD™ exhibits 99% antimicrobial activity and supports Zentek's healthcare commercialization strategy.
Zentek Ltd. (NASDAQ:ZTEK) has secured an initial order of ZenGUARD™ coated masks from Mark's, a leading Canadian retailer. This partnership will enhance the product's visibility in over 380 stores across Canada and online, offering a high-quality, Canadian-made option for safety wear. ZenGUARD™ provides 99% antimicrobial activity, including against COVID-19, positioning Zentek as a key player in innovative healthcare solutions. The collaboration may also open doors for future applications of Zentek's nanotechnologies.
Zentek Ltd. (Nasdaq:ZTEK; TSX-V:ZEN) has engaged The Benchmark Company as a strategic financial advisor for potential transactions related to its Albany Graphite Deposit in Northern Ontario. The engagement comes amid growing interest in North American sourced battery-grade graphite. CEO Greg Fenton emphasized the importance of Benchmark's expertise in evaluating commercial opportunities. Zentek owns 100% of the Albany Deposit and continues to focus on developing healthcare solutions, including the antimicrobial coating ZenGUARD.
Zentek Ltd. (NASDAQ:ZTEK) has announced a definitive supply agreement with EkoMed Global Inc. to enhance personal protective equipment (PPE) using Zentek's proprietary ZenGUARD™ coating. This collaboration aims to initially treat surgical masks with the ZenGUARD™ technology, known for its 99% antimicrobial activity. EkoMed's capabilities include the production of over 1.2 billion masks annually, positioning Zentek for greater market access and potential innovations in PPE. CEO Greg Fenton highlighted the strategic importance of this partnership for expanding ZenGUARD™ sales globally.
Zentek Ltd. (NASDAQ: ZTEK), a Canadian intellectual property development firm, has announced the successful completion of Phase 1 testing for its ZenGUARD™-coated HVAC filters. Following this, the company will advance to Phase 2 testing under its Innovation Solutions Canada contract. Phase 1 confirmed the coating's effectiveness in reducing airborne organisms while maintaining airflow. The upcoming Phase 2 aims to further validate the coating's safety and efficacy in a classroom setting. This progression is significant for indoor air quality initiatives and commercialization efforts.
Zentek Ltd. (NASDAQ: ZTEK) has partnered with FTI Consulting to aid its U.S. market expansion, focusing on the regulatory approval process for its ZenGUARD™ nanotechnology. This partnership aims to navigate the complicated federal regulations and potentially launch ZenGUARD™, which boasts 99% antimicrobial activity, including against COVID-19. This announcement follows Zentek's recent debut on the NASDAQ, enhancing its strategy to commercialize innovative healthcare solutions.
Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN) has filed a provisional patent for a Graphene Oxide-Metal-Organic Framework (GO-MOF) aimed at enhancing fire retardant products. The company emphasizes environmentally friendly components and efficient production methods. Initial tests for the GO-MOF in fire retardants have shown promising results, indicating its potential application in various coatings and in creating lightweight, fire-resistant plastics for electric vehicles. Zentek's innovative approach enhances its value proposition in health and safety.
Zentek Ltd. (Nasdaq:ZTEK) announced the publication of its international patent application for ZenGUARD technology by the World Intellectual Property Office. This milestone reflects the company’s progress from scientific breakthrough to commercialization. The ZenGUARD technology, which exhibits 99% antimicrobial activity, including effectiveness against COVID-19, aims to enhance revenue potential through commercial opportunities. Zentek is scaling production in its Guelph facility and actively pursuing market opportunities for ZenGUARD, particularly in transmission prevention with coated masks.
FAQ
What is the current stock price of Zentek Ltd. (ZTEK)?
What is the market cap of Zentek Ltd. (ZTEK)?
What is Zentek Ltd. specialized in?
What is ZENGuard?
What recent advancements has Zentek made in healthcare?
Who are Zentek's key partners?
What is Triera Biosciences Ltd.?
What is the latest news about Zentek?
Where is Zentek located?
What industries does Zentek serve?
What technology platforms does Zentek use?
How can I contact Zentek for more information?
